Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.

被引：2
|
作者：
Harrington, Kevin Joseph
Kong, Anthony
Mach, Nicolas
Chesney, Jason Alan
Castelo, Beatriz
Rischin, Danny
Cohen, Ezra E. W.
Radcliffe, Hoi-Shen
Gumuscu, Burak
Snyder, Wendy
Siu, Lillian L.
机构：
[1] Royal Marsden Inst Canc Res NIHR Biomed Res Ctr, London, England
[2] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England
[3] Univ Hosp Geneva, Dept Oncol, Geneva, Switzerland
[4] Univ Louisville, Brown Canc Ctr, Louisville, KY 40292 USA
[5] La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain
[6] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[7] Univ Calif San Diego, San Diego, CA 92103 USA
[8] Amgen Inc, Uxbridge, Middx, England
[9] Merck & Co Inc, Kenilworth, NJ USA
[10] Amgen Inc, Thousand Oaks, CA 91320 USA
[11] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.6036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6036
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Cost-effectiveness (CE) analysis of pembrolizumab as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States (US).
    Ramakrishnan, Karthik
    Jain, Disha
    Gandhi, Jyotika
    Chirovsky, Diana Romana
    Borse, Rebekah
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] ATHENA: A multicenter phase II of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) - The HPV-negative cohort
    Fayette, J.
    Saada, E. B.
    DeMontfort, A.
    Karabajakian, A.
    Neidhardt, E. M.
    Borel, C.
    Burgy, M.
    Carinato, H.
    Delord, J-P.
    Betrian, S.
    Toussaint, P.
    Chatellier, T.
    Iharidon, T.
    Garin, G.
    Bernardin, M.
    Jaouen, L.
    Sondarjee, I.
    Perol, D.
    Blay, J-Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S851 - S852
  • [43] Patterns of radiological responses to anti-PD1 in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study
    Even, C.
    Bernard-Tessier, A.
    Texier, M.
    Said, O. Ben
    Iacob, M.
    Daste, A.
    Fayette, J.
    Zanetta, S.
    Lefebvre, G.
    Vinches, M.
    Johnson, A. C.
    Le Moal, L. Bozec
    Saada, E. B.
    Jallut, I.
    Garic, F.
    Monard, L.
    Bourhis, J.
    Guigay, J.
    Auperin, A.
    Ammari, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S851 - S851
  • [44] Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Greil, R.
    Rischin, D.
    Harrington, K. J.
    Soulieres, D.
    Tahara, M.
    de Castro, G.
    Psyrri, A.
    Baste, N.
    Neupane, P.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia, R., Sr.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Lin, J.
    Swaby, R. F.
    Gumuscu, B.
    Burtness, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S660 - S661
  • [45] Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study
    Yang, Hang
    Sun, Peng
    Wang, Yu
    Wang, Xicheng
    Liu, Yanyan
    Peng, Jiyong
    Zhou, Hui
    Li, Yajun
    Zhang, Hong
    Hu, Jianbing
    Zhang, Bing
    Lin, Shunhuan
    Yang, Chunwei
    Li, Weidong
    Liu, Yanping
    Ji, Meng
    Zhao, Jinghua
    Xue, Jianfei
    Huang, Jiajia
    Li, Zhiming
    ORAL ONCOLOGY, 2025, 162
  • [46] Real-world time on treatment analysis of pembrolizumab treated recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC) patients stratified by ECOG PS in the United States.
    Black, Christopher Matthew
    Wang, Liya
    Ramakrishnan, Karthik
    Turzhitsky, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18007 - E18007
  • [47] Tpextreme Randomized Trial: TPEX Versus Extreme Regimen in 1st Line Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (R/M HNSCC), Updated Analysis
    Keilholz, U.
    Guigay, J.
    Fayette, J.
    Mesia, R.
    Lafond, C.
    Saada-Bouzid, E.
    Geoffrois, G.
    Martin, L.
    Cupissol, D.
    Capitain, O.
    Castanie, H.
    Vansteene, D.
    Schafhausen, P.
    Arvis, Dubos C.
    Even, C.
    Sire, C.
    Delhommeau, M.
    Michel, C.
    Bourhis, J.
    Auperin, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 230 - 230
  • [48] Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study
    Iglesias Docampo, L.
    Baste Rotllan, N.
    Oliva Bernal, M.
    Carral Maseda, A.
    Perez Segura, P.
    Medina Colmenero, A.
    Cirauqui Cirauqui, B.
    Arrazubi Arrula, V.
    Martinez Trufero, J.
    Gutierrez Calderon, V.
    Garcia Castano, A.
    Rubio-Casadevall, J.
    Basterretxea, L.
    Alvarez Cabellos, R.
    del Barco Morillo, E.
    Bruixola, G.
    Flor, M. J.
    Assaf Pastrana, J. D.
    Caballero Daroqui, J.
    Mesia Nin, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S624 - S624
  • [49] Pembrolizumab plus anlotinib as first-line treatment in patients of CPS≥1 with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
    Gui, L.
    He, X.
    Yang, J.
    Liu, P.
    Qin, Y.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1524 - S1524
  • [50] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study
    Gui, Lin
    Chen, Xinrui
    Xie, Zucheng
    He, Xiaohui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345